Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

20081,428 citationsJournal Articlebronze Open Access

Authors

Bengt I. Eriksson · Sahlgrenska University Hospital

Lars C. Borris · Aarhus University Hospital

Richard J. Friedman · Medical University of South Carolina

Sylvia Haas · Technical University of Munich

Menno V. Huisman · Leiden University Medical Center

Ajay K. Kakkar · Thrombosis Research Institute

Tiemo J. Bandel

Abstract

A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles. (ClinicalTrials.gov number, NCT00329628.)

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Atrial Fibrillation Management and Outcomes Acute Myocardial Infarction Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 358, Issue 26, pp. 2765-2775

DOI: 10.1056/nejmoa0800374

Field-Weighted Citation Impact: 69.63